Skip to content
Psychiatrist.com Logo
  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Advanced Search

Menu

  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Sign in Subscribe

Clinical Topics

View All
  • Addiction
  • ADHD
  • Alzheimer’s Disease
  • Anxiety
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Neurology
  • OCD
  • Psychopharmacology
  • PTSD and Trauma
  • Schizophrenia/Schizoaffective Disorders
  • Sleep
  • Tardive Dyskinesia
  • View All

Collections

View All
  • Academic Highlights
  • Auvelity: Information from Industry
  • Banner Alzheimer’s Institute
  • Clinical & Practical Psychopharmacology
  • Early Career Psychiatrists
  • Focus on Childhood and Adolescent Mental Health
  • Focus on Geriatric Psychiatry
  • Focus on Psychotherapy
  • Focus on Suicide
  • Focus on Psychosis
  • Focus on Women’s Mental Health
  • Rounds in the General Hospital
  • UZEDY: Information from Industry
  • View All
Back to top Open menu arrow
Download PDF Reprints
No sections available

The Journal of
Clinical Psychiatry

Free access
Sexual Dysfunction

Letter to the Editor February 28, 1999

Hyperprolactinemia and Male Sexual Dysfunction

William M. Glazer; Ruth A. Dickson

J Clin Psychiatry 1999;60(2):125-125

Article Abstract

Letter to the Editor

Hyperprolactinemia and Male Sexual Dysfunction

 

About the Authors

  • William M. Glazer
    View full profile
  • Ruth A. Dickson
    View full profile
Download Free PDF

This PDF is free for all visitors!

Related News Articles

Investigating The Forces Behind Celibacy Weekly Mind Reader: What Do Hair Pulling and PTSD Have in Common? Weekly Mind Reader: Sleep and Substance Use Disorders

Sponsored

PsychCase360: Choosing the Right Long-Acting Injectable for Patients With Schizophrenia
Explore two real-world schizophrenia cases with Roueen Rafeyan, MD and Melissa Vitale, PMHNP as they discuss challenges with medication adherence, transitioning to long-acting injectables (LAIs), and personalizing treatment strategies to improve patient outcomes.

Related JCP Articles

Gepirone-ER and Sexual Function in Patients with MDD Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia Aerobic Exercise for Erectile Dysfunction

Related PCC Articles

Managing Psychotropic Medication–Induced Priapism Sexsomnia and Dhat Syndrome in an Adolescent Male Role of Anxiety, Depression, Eating Attitudes, and Mindfulness in Sexual Dysfunction
Cover of The Journal of Clinical Psychiatry, September 2025 issue, featuring article titles on postpartum distress, aripiprazole monohydrate injectables for schizophrenia and bipolar disorder, and other psychiatric topics.

Vol 86 • 2025 • Number 3

Read the Current Issue

Original Research

Treatment Use and Preference in a Diverse Sample of Women With Mood Disorders

Original Research

Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders

Original Research

Niacin-Induced Response in Early Psychosis

Original Research

Early Ketamine Response Reduces Suicidal Events at 3 Months

Letter to the Editor

Suicide Risk among Patients with Bipolar Disorder: Sleep Disruption versus Benzodiazepine Use

Original Research

Effect of Nature Videos on the Burden of Caregivers of Patients with Dementia

View current Issue

Related Articles

PCC
SSRI-Related Sexual Dysfunction
Letter to the Editor

SSRI-Related Sexual Dysfunction

June 20, 2024

The authors discuss 2 SSRI-related sexual dysfunction syndromes: post-SSRI sexual dysfunction and persistent genital arousal disorder.
Ahmed Naguy, Bibi Alamiri
PCC
Psychotropic-Related Sexual Dysfunction: Clinical Insights
Letter to the Editor

Psychotropic-Related Sexual Dysfunction: Clinical Insights

December 21, 2023

Clinicians should be cognizant of and avidly screen for psychotropic-related sexual dysfunction during routine follow-up clinic visits.
Ahmed Naguy
PCC
Letter to the Editor

Oseltamivir-Associated Behavioral Changes

May 10, 2018

Oseltamivir (Tamiflu) is widely used for the treatment of influenza. However, adverse neuropsychiatric effects, including behavioral changes and perceptional disturbance, have been observed in oseltamivir-treated patients. Here, read about...
Kuo-Hsuan Chung, Yu-Jui Huang, Shih-Yun Lin, et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases
Promotional banner for a video titled “Choosing the Right LAI for Patients With Schizophrenia” featuring headshots of Roueen Rafeyan, MD, and Melissa Vitale, PMHNP, with a “Watch Now” button.

Subscribe to read
more articles

Subscribe
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

ELSEWHERE:

  • ABOUT
  • ADVERTISERS
  • MEDIA RELATIONS
  • REPRINTS & PERMISSIONS
  • CONTACT US
  • CUSTOMER SUPPORT

FOLLOW US:

  • X
  • FACEBOOK
  • INSTAGRAM
  • LINKEDIN
  • SIGN IN

  • JOIN THE EMAIL LIST


SUBSCRIBE NOW
An image of the Psychiatrist.com logo mark
  • Privacy Policy
  • Terms of Use
  • Physicians Postgraduate Press, Inc.
  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • © Copyright 2025 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians
  • Sitemap